Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma

Fig. 1

Study Schema. This is a randomized, non-comparative Phase II study designed to detect pathologic and immunologic biomarkers of response to checkpoint blockade in resectable, treatment naive primary or locally recurrent (a) dedifferentiated liposarcoma (DDLPS) of the retroperitoneum and (b) undifferentiated pleomorphic sarcoma (UPS) of the trunk or extremities

Back to article page